HopeStage
Back to all studies
TerminatedNCT01717040

Pioglitazone for the Treatment of Depression in bipolarity

Medication studyAges 18+United States
The study in practice

Understand this study

Who could participate?

Listed age limits: from 18 years.

Listed locations
ClevelandSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateSeptember 2012
Recruitment status
Terminated
Enrollment listed in the registry
37
Sponsor
University Hospitals Cleveland Medical Center
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT01717040
Official title
Show the full official title

Double-Blind, Placebo-Controlled Trial of Pioglitazone for Bipolar Depression

Recruitment & locations

Terminated

Cleveland

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University Hospitals Cleveland Medical Center, a university.

Does this study involve medication?

Yes. The study involves medication, including Pioglitazone and Placebo.

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies